Coagulation studies during therapeutic application of arvin.
D000347:Afibrinogenemia / Q000139:chemically induced; D000721:Ancrod / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012103:Batroxobin / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000139:chemically induced; D001791:Blood Platelet Disorders / Q000139:chemically induced; D001792:Blood Platelets / Q000187:drug effects; D004351:Drug Resistance; D010450:Endopeptidases / Q000627:therapeutic use*; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D010974:Platelet Aggregation / Q000187:drug effects; D013917:Thrombin; D013921:Thrombocytopenia / Q000139:chemically induced; D014443:Tyrosine
D014443:Tyrosine; D005340:Fibrinogen; D010450:Endopeptidases; D000721:Ancrod; D012103:Batroxobin; D013917:Thrombin